Članak koji je dostavljen izgleda kao tehničko uputstvo vezano za funkcionalnost web stranice, a ne za izvještaj o vijestima.
Procjena pristranosti (Sredina): Sadržaj je čisto informativni i tehnički, pruža upute za navigaciju na web stranicama.
Zašto činjenice (50): The article mentions AstraZeneca considering the acquisition of Bristol-Myers Squibb, but lacks specific details, dates, or sources to verify the claim. The text appears to be a headline or snippet from a Slovenian news source, possibly Bloomberg Adria, but no primary source is available. Cross-sour
Zašto objektivnost (30): The article is brief and lacks contextual depth. It presents a potential business development without analysis or balance. The tone is neutral but lacks sufficient detail to assess objectivity properly.






